Catalent is vulnerable to facility closures whether from natural disasters or manufacturing issues, and a warning letter from the FDA or other regulatory agency can result in manufacturing delays or ...

Quanta Dialysis Technologies has raised $60 million to expand its U.S. commercial presence for its Quanta dialysis system.

With nearly $14 billion sales in 2023, it shows no signs of slowing down, much to the delight of its Danish manufacturer, ...

Sumitomo Mitsui Trust Group Inc. boosted its holdings in shares of Vanguard Total Stock Market ETF (NYSEARCA:VTI – Free ...

Capital Group Global Growth Equity is for global diversification in growth stocks with top tech and healthcare holdings.

Quanta Dialysis Technologies, a leader in transforming kidney care through its award-winning Quantatm Dialysis System, has successfully closed its oversubscribed Series E Preferred Stock financing ...

Below is our Corporate / M&A decisions update covering decisions in the second quarter of 2024. Decisions from the Delaware Court of Chancery ...

Polen Capital, an investment management company, released its “Polen Global Growth Strategy” third-quarter 2024 investor ...

German drugmaker Evotec is attracting takeover interest from U.S.-based Halozyme Therapeutics, Bloomberg News reported on Thursday. Halozyme has recently expressed interest in acquiring Evotec at ...

Halozyme Therapeutics said on Thursday it has proposed to buy German drug developer Evotec for about 2 billion euros ($2.10 billion), to bulk up its drug discovery and development portfolio.

This health news summary explores various pharmaceutical developments including Novo Nordisk's phasing out of insulin pens, a ...

A roundup of top health news highlights Novo Nordisk's $16.5 billion deal scrutiny, Amgen's weight-loss drug controversy, ...